Status:
RECRUITING
UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease
Lead Sponsor:
The Hospital for Sick Children
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Genome Canada
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
Up to 18 years
Brief Summary
Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic ...
Detailed Description
UCAN CAN-DU is a multicenter observational cohort study that will collect prospective data from children with arthritis. Biologic samples, clinical data and patient reported outcomes will be collected...
Eligibility Criteria
Inclusion
- Cohort 1: - Biologic Basis of JIA
- ≤18 years\*
- Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment
- Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis
- Cohort 2 - Start Biologics
- JIA diagnosis as per ILAR criteria (all subtypes)
- ≤18 years\*
- Active arthritis
- For sJIA, active disease not necessarily with arthritis.
- Time of start, restart or switch biologic therapy: e.g. failure, insufficient/partial response or intolerance
- Cohort 3 - Stop Biologics
- JIA diagnosis as per ILAR criteria (all subtypes)
- ≤18 years\*
- Inactive disease
- Discontinuing/tapering biologics for inactive disease
- Cohort 4: Extreme Phenotypes
- Unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations
- High suspicion of genetic contribution
- Severely affected patients with difficult to control disease (ie failure of multiple biologics)
Exclusion
- Cohort 1 :
- Arthritis explained by another diagnosis
- Joint injections as previous treatment less than 4 weeks prior to enrollment
- Cohort 2:
- Arthritis explained by any other cause
- Start on biologics as an indication for uveitis only
- Cohort 3:
- \- Tapering scheme \> 12 months to complete biologics stop
- Cohort 4:
- \- Arthritis explained by another diagnosis
Key Trial Info
Start Date :
August 24 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2027
Estimated Enrollment :
4100 Patients enrolled
Trial Details
Trial ID
NCT06560606
Start Date
August 24 2018
End Date
March 30 2027
Last Update
August 19 2024
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Alberta Children's Hospital - University of Calgary
Calgary, Alberta, Canada, T3B 6A8
2
Stollery Children's Hospital
Edmonton, Alberta, Canada, T6G 2B7
3
BC Children's Hospital
Vancouver, British Columbia, Canada, V6H 3N1
4
Children's Hospital Health Science Centre Winnipeg
Winnipeg, Manitoba, Canada, R3A 1R9